- Nurix Therapeutics reported a **net loss of $86.4 million**, or **($1.03) per share**, on **revenue of $7.9 million** for the third quarter ended August 31, 2025.  **[1549595_0001549595-25-000112_nrix-20251009xexx991.htm:3]** **[1549595_0001549595-25-000112_nrix-20251009xexx991.htm:5]** 
- As of August 31, 2025, the company maintained a strong financial position with **$428.8 million in cash, cash equivalents, and marketable securities**.  **[1549595_0001549595-25-000112_nrix-20251009xexx991.htm:3]** 
- The company announced plans to initiate **pivotal trials for bexobrutideg** in relapsed/refractory CLL patients in the second half of 2025, with a strategy for potential accelerated approval.  **[1549595_0001549595-25-000112_nrix-20251009xexx991.htm:0]** **[1549595_0001549595-25-000112_nrix-20251009xexx991.htm:1]** **[1549595_0001549595-25-000112_nrix-20251009xexx991.htm:2]** 
- Preclinical data for **GS-6791**, a novel IRAK4 degrader developed in collaboration with Gilead, was presented at EADV 2025, demonstrating potent pathway inhibition and efficacy in a dermatitis model.  **[1549595_0001549595-25-000112_nrix-20251009xexx991.htm:0]** **[1549595_0001549595-25-000112_nrix-20251009xexx991.htm:1]**

Nurix Therapeutics Reports Q3 2025 Financial Results and Clinical Development Plans

- Nurix Therapeutics is advancing **Bexabritadeg**, a highly potent and specific BTK degrader, for autoimmune diseases, with clinical proof-of-concept data in CLL patients with autoimmune hemolytic anemia expected in **2026**.  **[1549595_2145623_1]**  A new tablet formulation is undergoing a multiple ascending dose study, and an IND filing for an autoimmune indication is planned for **2026**.  **[1549595_2145623_2]** 
- The company reported **$485 million in cash** at the end of the last quarter, providing funding through **mid-2027**.  **[1549595_2145623_5]** 
- Nurix is progressing its collaborative I&I pipeline, including a clinical-stage **IRAK4 degrader with Gilead Sciences** and a preclinical **STAT6 degrader with Sanofi S.A.**.  **[1549595_2145623_3]**  Gilead Sciences is presenting preclinical data for the IRAK4 degrader at the EADV conference this week, with clinical information anticipated in **2026**.  **[1549595_2145623_4]** **[1549595_2145623_5]** 
- Nurix expects to transition to a **phase 3 company in 2026** with Bexabritadeg, which is launching into pivotal studies.  **[1549595_2145623_5]**

Nurix Therapeutics Provides Update on Immunology and Inflammation Pipeline and Financial Position

- Neurix Therapeutics (NRIX) announced its **Phase III trial design** for bexabrutinib (BexDeg), a targeted protein degrader, which will be a randomized 1:1 study against investigator choice control arms (pirtobrutinib, IR, or BR) in **400 to 500 patients** across **20 to 30 countries**.  **[1549595_tx_381580_2]**  This trial targets the **second-line market**, estimated at **$2 billion annually** and projected to grow to **$5 billion**.  **[1549595_tx_381580_3]** 
- The company also plans a single-arm **Phase II trial** with approximately **100 patients** for potential accelerated approval of bexabrutinib, with enrollment expected to be rapid.  **[1549595_tx_381580_2]** **[1549595_tx_381580_4]** 
- Bexabrutinib has demonstrated strong efficacy with an **80% overall objective response rate** in third-line plus patients and an **84.2% ORR in Waldenstrom's**, while maintaining a **very well-tolerated safety profile** with no dose-limiting toxicities.  **[1549595_tx_381580_2]** **[1549595_tx_381580_5]** 
- Neurix is advancing other key pipeline assets, including an **IRAK4 degrader** with Gilead and a **STAT6 degrader** with Sanofi, both of which have received significant funding and are in healthy volunteer studies or advanced preclinical stages.  **[1549595_tx_381580_1]** **[1549595_tx_381580_7]**

Neurix Therapeutics Unveils Bexabrutinib Phase III Trial Design and Pipeline Updates

- Nurix Therapeutics, Inc. filed an 8-K on **September 3, 2025**, which included an investor presentation detailing updates on its clinical development plans.  **[1549595_0001549595-25-000108_nrix-20250903.htm:0]** **[1549595_0001549595-25-000108_nrix-20250903.htm:1]** 
- The company's investigational drug, **bexobrutideg (NX-5948)**, an oral, brain-penetrant degrader of Bruton's tyrosine kinase, is currently being evaluated in a **Phase 1 clinical trial** for patients with relapsed or refractory B cell malignancies.  **[1549595_0001549595-25-000108_nrix-20250903.htm:1]** 
- In its Phase 1a trial, bexobrutideg showed a **clinically meaningful objective response rate (ORR) of 80.9%** (95% CI: 66.7–90.9) in 47 relapsed/refractory CLL patients, with a tolerable safety profile.  **[1549595_0001549595-25-000108_nurixinvestorpresentatio.htm:4]** 
- Nurix plans to initiate a potentially pivotal **Phase 2 study in H2 2025** and a subsequent **Phase 3 confirmatory trial** for bexobrutideg, aiming to expand into a **$15B+ global market**.  **[1549595_0001549595-25-000108_nurixinvestorpresentatio.htm:5]**   
- The company expects to fund its operations into the **first half of 2027**.  **[1549595_0001549595-25-000108_nurixinvestorpresentatio.htm:1]**

Nurix Therapeutics (NRIX)